Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021...
HANGZHOU and SHAOXING, China, Oct. 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the results of Phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB) will be presented in oral parallel session at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases (AASLD)....
Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline
HANGZHOU, China and SAN FRANCISCO, Oct. 12, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the closing of an $70 million Series C financing. The financing round was co-led by IDG Capital, Loyal Valley Capital and LYFE Capital. Sciwind plans to use...
EVERSANA™ named a Great Place to Work for third consecutive year in U.S.; earns valuable recognition in Canada, China and India
CHICAGO, Oct. 11, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, is celebrating its designation as a Great Place to Work® by the global authority in workplace culture. Based on an anonymous survey to more than 3,000 EVERSANA employees worldwide, the company earned...
Twist Alliance Pan-Cancer Methylation Panel Global Launch Event – A Strategic Collaboration Between AnchorDx and Twist Bioscience for Pan-Cancer Liquid Biopsy
GUANGZHOU, China, Oct. 11, 2021 /PRNewswire/ -- The Twist Alliance Pan-Cancer Methylation Panel (Pan-Cancer Panel), a solution for pan-cancer study including DNA methylation library preparation and targeted enrichment for next-generation sequencing (NGS), was launched globally on September 24th (US time). The Pan-Cancer Panel was developed over a two-year period by AnchorDx in collaboration with...
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres® Y-90 resin microspheres in China
WOBURN, Mass., Oct. 11, 2021 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in China was successfully performed for a patient with hepatocellular carcinoma (HCC) on Sept. 28, 2021. The...
CGM lab software modernizes healthcare in Timor-Leste
CGM SCHUYLAB improves patient care in low- and middle-income countries OWINGS MILLS, Md., Oct. 11, 2021 /PRNewswire/ -- A global leader in e-health technology, CompuGroup Medical (CGM) worked this summer with Timorese scientists and Australia's Menzies School of Health Research to improve patient care and streamline the diagnostic laboratory process in the...
Sai Life Sciences presents mid-term report on Sai Nxt initiative; reveals upsurge in capabilities
- Completes two-thirds of its investment target of US$150M - Demonstrates a leap forward in capabilities across all focus areas – People, Processes, and Infrastructure HYDERABAD, India, Oct. 11, 2021 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development and Manufacturing Organisation (CRO-CDMO), today presented a midterm report on...
RhoVac retains international investment bank as advisor for desired RV001 transaction
STOCKHOLM, Oct. 11, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today, October 11, 2021, that it has retained the services of Stifel Nicolaus Europe Limited ("Stifel"), a global investment bank, as its exclusive financial adviser in connection with the planning, execution and closing of a potential transaction or partnership deal (a "transaction"). Such a...
Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma
SUZHOU, China, Oct. 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the clinical trial of ALK-1 antibody (GT90001C) and Nivolumab (Opdivo®) combination therapy for the treatment of systemic therapy naïve patients with advanced hepatocellular carcinoma ("HCC") was approved by the National Medical Products Administration...
18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA
GENEVA, Oct. 11, 2021 /PRNewswire/ -- 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions...
